New in­fla­tion-linked drug re­bates go in­to ef­fect on Sat­ur­day

Be­gin­ning to­mor­row, bio­phar­ma com­pa­nies can be charged re­bates for any new drug price in­creas­es ris­ing faster than the rate of in­fla­tion.

The new re­bates are part of the new­ly signed In­fla­tion Re­duc­tion Act, which in­tro­duces this new re­quire­ment that man­u­fac­tur­ers pay re­bates to Medicare for Part D drugs whose price in­creas­es ex­ceed in­fla­tion, and in Jan­u­ary 2023, the same will oc­cur with Part B drugs.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN